Roger Pomerantz sold $1.57M worth of shares in Seres Therapeutics, Inc. in June 2018

Jul 08, 2018
Insider Transactions
Background Information
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.